Immuno-Oncology

Immuno-Oncology is a subgroup of the MASCC Neutropenia, Infection & Myelosuppression Study Group


Leadership
CHAIR
Bernardo Rapoport, MD, MMED
South Africa
  VICE-CHAIR
Mario Lacouture, MD
USA

>> How to Join
To join a Study Group, login to your account, and click the Manage My Account/Profile.  Scroll down to your profile data and select "Edit". Then select the study group as one of your three Study Group selections. Click SAVE.

To join a Subgroup, you must be a member of the parent Study Group. Login to your account, and click Manage My Account/Profile.  Scroll down to your profile data and select "Edit". Then select the subgroup. Click SAVE.
Subgroups do not count toward your three Study Group selections.
>> More information or to contact Study Group/Subgroup leadership
To contact a Study Group or Subgroup Leader, search for their name in the member directory.
For more information or questions, contact the MASCC office at [email protected].

Mission and Goals

The emergence of immune checkpoint inhibitors (ICIs) that target the cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) and programmed cell death protein-1/ ligand 1 (PD-1/PD-L1) pathway has significantly improved outcomes for patients with a variety of malignancies. By blocking the inhibitory signaling pathway of T-cells, ICIs are associated with a diverse spectrum of immune-related adverse events (irAEs) involving multiple organ systems. This new Subgroup on Immuno-Oncology (IO) comprises Study Group members interested in organ systems from disciplines related to immunotherapy-related events, including, but not limited to, gastroenterology, dermatology, neurology, hematology, rheumatology, endocrinology, nephrology, and emergency medicine.

The goal of the Subgroup is to create a multidisciplinary team that brings together the best information and ideas about this new and growing field. Aims are to develop educational sessions at MASCC Annual Meetings and research projects involving MASCC members. The Subgroup will also serve as a resource for information and contacts with companies involved in immunotherapies that might help fund MASCC projects. The IO Subgroup will meet every year at the MASCC Annual Meeting, beginning in 2019. The first project of the Subgroup is to develop position papers for the management of corticosteroid resistant or refractory adverse events. Future projects will be developed on the basis of members’ interests.


 Subgroup Activities
Subgroup News

 

Last Updated on Wednesday, June 23, 2021 10:28 AM